In prostate cancer, Ebrahimi et al. (2022) have demonstrated through in vitro and in vivo experiments that Aprepitant can inhibit cell proliferation and migration via the SP/NK-1R pathway and significantly prolong the survival time of mice (Ebrahimi et al., 2022). This evidence concerns the gene TACR1 and prostate cancer.